

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website : www.sunpharma.com
CIN : L24230GJ1993PLC019050



Date: September 05, 2019

To,

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
NSE Code – SUNPHARMA

BSE Limited
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.
BSE Code– 524715

Dear Sir/ Madam,

Re: Email dated September 4, 2019 received from BSE Limited (“BSE”)

and

Letter dated September 4, 2019 received from National Stock Exchange of India Limited (“NSE”)

Sub: Clarification on news item which appeared in the “www.business-standard.com” dated September 04, 2019 captioned “Sun Pharma slides 4% on report of Sebi ordering forensic audit”

1. This is in relation to the captioned email/ letter received from BSE and NSE respectively, seeking clarification from Sun Pharmaceutical Industries Limited (“**Company**”) regarding a media article that appeared on the website of Business Standard on September 4, 2019 captioned “*Sun Pharma slides 4% on report of Sebi ordering forensic audit*” (“**News Article**”).
2. At the outset, please note that the Company has always sought to comply with its regulatory obligations, including, making appropriate disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 (“**SEBI LODR Regulations**”).

The Company is not aware of any information that could explain the movement in the price of the scrip as referred to the said News Article. Additionally, you may also note that a forensic audit has been ordered by SEBI w.r.t. the financial statements of Sun Pharmaceutical Industries Ltd. for the financial years ending March 31, 2016, March 31, 2017 and March 31, 2018. The said forensic audit is presently ongoing.

3. As an organization, we are committed to adhering to all applicable legal and regulatory requirements and will ensure that any material developments in this regard are promptly notified to all our stakeholders in line with Regulation 30 of the SEBI LODR Regulations.
4. The above is for your information and records.

Thanking you.

Yours sincerely,

For Sun Pharmaceutical Industries Limited,



Ashok I Bhuta

Compliance Officer